ACE2 and COVID-19: Short after the first cases of COVID-19, SARS-CoV-2 was identified as the aetiological agent of the disease (Zhou et al., 2020; Zhu et al., 2020), and angiotensin I converting enzyme 2 (ACE2) was demonstrated to be the viral entry receptor for this virus (Qiu et al., 2020; Yan et al., 2020).